In part two of this 2-episode mini-series, our panelists discuss the recent approval of tenapanor for hyperphosphatemia management in patients on dialysis by the United States Food & Drug Administration (FDA). Tune into this discussion where our expert panelists share how the phosphate absorption inhibitor (PAI) works, factors to consider when integrating this agent into a patient’s treatment regimen, and how it may impact hyperphosphatemia management moving forward.
Learning objectives:
Describe the primary pathways for phosphate absorption.
Explain the potential role(s) for a phosphate absorption inhibitor (PAI) for people with CKD who are on dialysis.
Host: Sam Kant, MD
Guests: Alexander Leidner, MD; Annabel Biruete, RD, PhD; Alex Berrios
Supported by a grant from Ardelyx.
Don't miss Part 1 in this series! Listen to: Patient & Clinician Experiences with Hyperphosphatemia: The Current Landscape

Ver todos los episodios